BCI
CRSP icon

Brinker Capital Investments’s CRISPR Therapeutics CRSP Stock Holding History

Brinker Capital Investments’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,270
Closed -$631K – 1917
2026
Q1 		$631K Buy
13,270
+679
+5% +$35.8K 0.01% 1355
2025
Q4 		$660K Buy
12,591
+4,489
+55% +$269K ﹤0.01% 1462
2025
Q3 		$525K Sell
8,102
-15
-0.2% -$861 ﹤0.01% 1530
2025
Q2 		$395K Buy
+8,117
New +$314K ﹤0.01% 1590

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Brinker Capital Investments's CRSP Position: Q2 2026 in Review

Brinker Capital Investments sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 13,270 shares — an estimated $631K sold.

Brinker Capital Investments first reported a position in CRSP in Q2 2025 and held it in 4 quarters. The position peaked at $660K in Q4 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Brinker Capital Investments reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Brinker Capital Investments sold 13,270 CRISPR Therapeutics shares in Q2 2026, an estimated $631K.
  • Brinker Capital Investments first reported a position in CRISPR Therapeutics in Q2 2025 and held it in 4 quarters.
  • Brinker Capital Investments's CRISPR Therapeutics position peaked at $660K in Q4 2025.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.